Spea.Bo
SPEA.BO operates in the Pharmaceuticals & Medical Research industry, focusing on the development and commercialization of pharmaceutical products and medical research solutions.
Business. SPEA.BO operates in the Pharmaceuticals & Medical Research industry, focusing on the development and commercialization of pharmaceutical products and medical research solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SPEA.BO operates in the Pharmaceuticals & Medical Research industry, focusing on the development and commercialization of pharmaceutical products and medical research solutions.
SPEA.BO maintains a strong liquidity position, as evidenced by a current ratio of 5.5, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. However, the company reported a negative operating cash flow of -64,320,000 INR, which may signal short-term cash flow challenges despite its high current ratio. The debt-to-equity ratio of 0.16 suggests a conservative capital structure, with a relatively low proportion of debt compared to equity, which reduces financial risk.
In terms of profitability, SPEA.BO demonstrates a return on equity (ROE) of 23.5% and a return on assets (ROA) of 17.98%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting that the company is outperforming its peers in terms of profitability.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. The lack of geographic diversification is a notable concern, as it limits the company's ability to mitigate regional economic fluctuations.
Looking at the growth trajectory, SPEA.BO has shown a consistent increase in revenue, with a total revenue of 582,714,000 INR. While the company has not provided specific outlook figures for the next fiscal year, the current financial performance suggests a positive trend. The capital expenditure of -6,071,000 INR indicates that the company is investing in its operations, which could support future growth.
The risk assessment for SPEA.BO highlights a medium liquidity risk, primarily due to the negative operating cash flow. The company also faces a low dilution risk, as there is no indication of significant share issuance or dilution in the near term. The key flag of net cash being negative after subtracting total debt is a concern, as it may affect the company's ability to meet its short-term obligations.
Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's financial statements and disclosures have not revealed any significant legal or regulatory issues that could impact its operations. The absence of recent major events suggests a stable operational environment for SPEA.BO.
- SPEA.BO has a strong liquidity position with a current ratio of 5.5, indicating sufficient current assets to cover liabilities.
- The company's profitability is robust, with a return on equity of 23.5% and a return on assets of 17.98%.
- Revenue is concentrated in a single segment, which may increase risk exposure.
- The company is investing in its operations, as indicated by a capital expenditure of -6,071,000 INR.
- SPEA.BO faces a medium liquidity risk due to a negative operating cash flow.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SPEA.BO Market data — financials · 2026-05-29